21 September 2016 - AstraZeneca has suffered a setback after being forced to withdraw an application for a key ovarian cancer drug to be approved, citing “differences of opinion” with the European regulator.

The FTSE 100 pharmaceuticals firm was hoping that ovarian cancer drug cediranib, which had passed final clinical trials, would get the green light from the EMA to use in combination with chemotherapy.

“In the end there were differences of opinion with the regulator,” a spokesman said. "We went back and forth but sometimes you just can’t change someone’s mind."

Read Telegraph article